Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

The Effects of Midazolam, Dexmedetomidine, and Esketamine on Bispectral Index and Raw Electroencephalogram in Patients Under Propofol-Remifentanil Baseline Anesthesia

8 luglio 2026 aggiornato da: Li Zhao, China-Japan Friendship Hospital

This prospective, single-center, randomized interventional study aims to investigate the effects of commonly used adjunct anesthetic drugs on the Bispectral Index (BIS) and electroencephalographic (EEG) activity during total intravenous anesthesia.

BIS monitoring is widely used to estimate the depth of anesthesia. However, previous studies suggest that certain anesthetic drugs, particularly dexmedetomidine and esketamine, may alter BIS values independently of the patient's actual level of consciousness. As a result, BIS readings may not always accurately reflect anesthetic depth when multiple drugs are administered together.

Adult patients undergoing elective laparoscopic cholecystectomy under standardized propofol-remifentanil anesthesia will be randomly assigned to receive one of the following adjunct drugs: midazolam, dexmedetomidine, esketamine, or no additional study drug (control group). Continuous BIS values and raw EEG signals will be recorded throughout the study period.

The primary objective is to compare changes in BIS values among different adjunct anesthetic drugs under otherwise similar anesthetic conditions. The study will also explore corresponding EEG characteristics associated with these changes. The findings are expected to improve understanding of drug-related differences in processed EEG monitoring and provide data for future development of more accurate anesthesia depth assessment methods.

Panoramica dello studio

Stato

Non ancora reclutamento

Condizioni

Intervento / Trattamento

Tipo di studio

Interventistico

Iscrizione (Stimato)

120

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

  • Cina
    • Beijing Municipality
      • Beijing, Beijing Municipality, Cina, 100029
        • China-Japan Friendship Hospital
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Adulto
  • Adulto più anziano

Accetta volontari sani

No

Descrizione

Inclusion Criteria:

  1. ASA physical status I-II;
  2. BMI 18-28 kg/m²;
  3. Scheduled for elective laparoscopic cholecystectomy, with an expected surgical duration from skin incision to completion of wound closure of ≥45 min;
  4. Planned to receive propofol-remifentanil total intravenous anesthesia, with routine intraoperative BIS monitoring and simultaneous acquisition of raw EEG signals;
  5. Voluntarily agrees to participate in this study, has signed the informed consent form, and is able to cooperate with the intervention and assessment procedures.

Exclusion Criteria:

  1. A confirmed history of psychiatric or neurological disorders, or use of antipsychotics, antidepressants, benzodiazepines, or other sedative-hypnotic drugs within 4 weeks before surgery;
  2. Cognitive impairment identified by Mini-Cog screening;
  3. Poorly controlled or untreated hypertension, sinus bradycardia, or severe cardiac conduction block;
  4. Acute angle-closure glaucoma;
  5. Known allergy to any required anesthetic drug;
  6. Difficulty in electrode placement or any condition that may interfere with EEG monitoring.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Diagnostico
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Separare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore attivo: Control Group
Participants receive standardized propofol-remifentanil total intravenous anesthesia without administration of the study adjunct anesthetic drug.
Droga: Propofol
Propofol will be administered as part of standardized total intravenous anesthesia in all study groups.
Droga: Remifentanil
Remifentanil will be administered as part of standardized total intravenous anesthesia in all study groups.
Sperimentale: Midazolam Group
Participants receive standardized propofol-remifentanil total intravenous anesthesia plus midazolam according to the study protocol.
Droga: Propofol
Propofol will be administered as part of standardized total intravenous anesthesia in all study groups.
Droga: Remifentanil
Remifentanil will be administered as part of standardized total intravenous anesthesia in all study groups.
Droga: Midazolam
Midazolam administered as an adjunct to standardized propofol-remifentanil total intravenous anesthesia according to the study protocol.
Sperimentale: Dexmedetomidine Group
Participants receive standardized propofol-remifentanil total intravenous anesthesia plus dexmedetomidine according to the study protocol.
Droga: Propofol
Propofol will be administered as part of standardized total intravenous anesthesia in all study groups.
Droga: Remifentanil
Remifentanil will be administered as part of standardized total intravenous anesthesia in all study groups.
Droga: Dexmedetomidine
Dexmedetomidine administered as an adjunct to standardized propofol-remifentanil total intravenous anesthesia according to the study protocol.
Sperimentale: Esketamine Group
Participants receive standardized propofol-remifentanil total intravenous anesthesia plus esketamine according to the study protocol.
Droga: Propofol
Propofol will be administered as part of standardized total intravenous anesthesia in all study groups.
Droga: Remifentanil
Remifentanil will be administered as part of standardized total intravenous anesthesia in all study groups.
Droga: Esketamine
Esketamine administered as an adjunct to standardized propofol-remifentanil total intravenous anesthesia according to the study protocol.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in Bispectral Index (BIS) value from the pre-intervention baseline
Lasso di tempo: Baseline and 5, 10, 15, 20, 25, 30 minutes after adjunct drug administration
Change in Bispectral Index value from the stable pre-intervention baseline will be compared among the four study groups after administration of the assigned adjunct anesthetic drug under standardized propofol-remifentanil total intravenous anesthesia. The pre-intervention baseline is defined as the stable BIS value immediately before administration of the assigned adjunct anesthetic drug. The Bispectral Index is a dimensionless electroencephalography-derived index ranging from 0 to 100, with lower values indicating deeper hypnotic states.
Baseline and 5, 10, 15, 20, 25, 30 minutes after adjunct drug administration

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in mean arterial pressure from pre-intervention baseline
Lasso di tempo: Baseline and 5, 10, 15, 20, 25, and 30 minutes after adjunct drug administration.
Change in mean arterial pressure (MAP) from the stable pre-intervention baseline will be compared among the four study groups after administration of the assigned adjunct anesthetic drug under standardized propofol-remifentanil total intravenous anesthesia.
Baseline and 5, 10, 15, 20, 25, and 30 minutes after adjunct drug administration.
Change in heart rate from pre-intervention baseline
Lasso di tempo: Baseline and 5, 10, 15, 20, 25, and 30 minutes after adjunct drug administration.
Change in heart rate (HR) from the stable pre-intervention baseline will be compared among the four study groups after administration of the assigned adjunct anesthetic drug.
Baseline and 5, 10, 15, 20, 25, and 30 minutes after adjunct drug administration.
Time from discontinuation of anesthetic drugs to airway device removal
Lasso di tempo: From discontinuation of anesthetic drugs to airway device removal, up to 60 minutes.
The time interval from discontinuation of anesthetic drugs to removal of the airway device will be recorded.
From discontinuation of anesthetic drugs to airway device removal, up to 60 minutes.
Time to Aldrete score of 10 in the post-anesthesia care unit
Lasso di tempo: From admission to the post-anesthesia care unit to achievement of an Aldrete score of 10, up to 2 hours.
The time from admission to the post-anesthesia care unit to achievement of an Aldrete score of 10 will be recorded. The Aldrete score ranges from 0 to 10, with higher scores indicating better post-anesthesia recovery.
From admission to the post-anesthesia care unit to achievement of an Aldrete score of 10, up to 2 hours.
Brice questionnaire assessment
Lasso di tempo: Before discharge from the post-anesthesia care unit, and at 24 and 48 hours after surgery.
The Brice questionnaire will be used to assess postoperative recall and awareness-related events.
Before discharge from the post-anesthesia care unit, and at 24 and 48 hours after surgery.
Postoperative pain score
Lasso di tempo: At admission to the post-anesthesia care unit, before discharge from the post-anesthesia care unit, and at 24 and 48 hours after surgery.
Postoperative pain intensity will be assessed using the numeric rating scale (NRS).
At admission to the post-anesthesia care unit, before discharge from the post-anesthesia care unit, and at 24 and 48 hours after surgery.
Postoperative analgesic medication use
Lasso di tempo: From admission to the post-anesthesia care unit to 48 hours after surgery.
Use of postoperative analgesic medications, including opioid and non-opioid analgesics (e.g., NSAIDs), in the post-anesthesia care unit and hospital ward will be recorded and compared among study groups.
From admission to the post-anesthesia care unit to 48 hours after surgery.

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in pre-specified electroencephalographic spectral features from baseline
Lasso di tempo: Baseline and 5, 10, 15, 20, 25, and 30 minutes after adjunct drug administration.
Pre-specified electroencephalographic spectral features, including alpha-to-delta power ratio, frontal alpha power, alpha peak frequency, and burst suppression ratio, will be evaluated and compared among study groups at baseline and after administration of the assigned adjunct anesthetic drug.
Baseline and 5, 10, 15, 20, 25, and 30 minutes after adjunct drug administration.
Change in electroencephalographic relative spectral power from baseline
Lasso di tempo: Baseline and 5, 10, 15, 20, 25, and 30 minutes after adjunct drug administration.
Relative power spectral density of delta, theta, alpha, beta, and gamma frequency bands will be compared among study groups at baseline and after administration of the assigned adjunct anesthetic drug.
Baseline and 5, 10, 15, 20, 25, and 30 minutes after adjunct drug administration.

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

China-Japan Friendship Hospital

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

30 giugno 2026

Completamento primario (Stimato)

30 giugno 2027

Completamento dello studio (Stimato)

30 dicembre 2027

Date di iscrizione allo studio

Primo inviato

26 giugno 2026

Primo inviato che soddisfa i criteri di controllo qualità

8 luglio 2026

Primo Inserito (Effettivo)

13 luglio 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

13 luglio 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

8 luglio 2026

Ultimo verificato

1 luglio 2026

Maggiori informazioni

Termini relativi a questo studio

Parole chiave

Termini MeSH pertinenti aggiuntivi

Altri numeri di identificazione dello studio

  • 2026-HX-40

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi